AFL Sues FDA Over Records on Adolescent Blockers
The American First Legal (AFL) filed a lawsuit against the Food and Drug Administration (FDA) on Friday, seeking access to records from the Biden administration. These records pertain to internal guidance regarding the use of adolescent blockers for children.
Previously, legal groups linked to Trump uncovered communications from the former administration through a Freedom of Information Act (FOIA) request. Following that, the AFL initiated another FOIA request specifically targeting the FDA’s internal guidance on the drugs’ use without condemnation.
Despite the existence of federal information requests, the FDA hasn’t been forthcoming, and the deadline for document preparation is quickly approaching.
“The Biden administration has promoted gender-denial treatments for children in America. It’s time to unveil what officials truly understood,” an AFL attorney shared with Scorinos.
Interestingly, to obtain the initial set of documents, the AFL had to resort to litigation, much like what they’re doing now with this FOIA request.
Records have shown that the Biden-era division of general endocrinology at the FDA supports the approval of adolescent blockers for children, even acknowledging the associated adverse effects, which include depression, suicide risks, and increased likelihood of seizures.
One FDA official mentioned in an email, revealed by the AFL, that “there is no doubt these drugs need to be sanctioned for gender transition,” despite clear warnings of potential mental health risks.
This information aligns with studies conducted elsewhere. For instance, researchers from the University of Texas examined a pool of over 107,000 individuals aged 18 and older who experienced gender discomfort. Their findings emphasized the necessity of “gender-sensitive mental health support” to tackle psychological risks linked to surgical transitions.
The data indicated that men who had undergone surgery faced a 25% rate of depression compared to nearly 12% in those who had not. Likewise, the anxiety rate in the surgical group was about 12.8%, while it stood at 2.6% for the non-operative demographic.
Similar trends were observed in women. Surgical patients recorded a depression rate of 22.9%, contrasting with 14.6% among those who hadn’t undergone surgery. Anxiety rates also demonstrated this discrepancy, with women post-surgery reporting a rate of 10.5%, compared to 7.1% for their non-operative counterparts.
Fox News Digital reached out to the FDA for a response but did not receive an immediate reply.
